Quince Therapeutics’ stock crashes on Phase III ataxia-telangiectasia failure
Quince Therapeutics’ stock has fallen by more than 90% after a Phase III trial of its Ataxia-Telangiectasia (A-T) drug failed…
Central Nervous System
-
-
J&J’s Caplyta doubles remission rate in MDD patients
Johnson & Johnson’s (J&J) Caplyta (lumateperone) plus antidepressants nearly doubled the likelihood of remission after six weeks, with benefit remaining…
-
Neumora’s Alzheimer’s disease agitation drug shows early success in Phase Ib trial
Neumora Therapeutics’ oral Alzheimer’s disease agitation drug has shown benefit, reducing agitation, in a Phase Ib trial. In the study…
-
Sanofi shares fall 6% after double setback for MS drug tolebrutinib
Sanofi’s experimental drug for multiple sclerosis (MS) has been hit with another US regulatory delay, a setback compounded by disappointing…
-
BMS delays Alzheimer’s readout for Cobenfy over “site irregularities”
Bristol Myers Squibb (BMS) has delayed the data readout from the Phase III ADEPT-2 trial of Cobenfy (xanomeline/trospium chloride) after…
-
Coya Therapeutics hopes for ALS Treg approval on Phase II trial
Coya Therapeutics is hoping to gain approval of its amyotrophic lateral sclerosis (ALS) disease-modifying therapy (DMT) based on its Phase…
-
Vesper Bio’s FTD candidate shows progranulin increase in Phase Ib/IIa trial
Vesper Bio’s frontotemporal dementia (FTD) drug has increased progranulin levels in a Phase Ib/IIa trial, showing its potential in slowing…
-
Multiple sclerosis: three trials to watch
September and October 2025 have proven busy for multiple sclerosis (MS) professionals, as many gathered at three major conferences to…
-
BridgeBio’s stock up as muscular dystrophy therapy meets Phase III endpoints
BridgeBio Pharma will seek US approval of its limb-girdle muscular dystrophy (LGMD) small molecule after the drug met its endpoints in…
-
FDA lifts clinical hold on Neurizon’s ALS drug
The US Food and Drug Administration (FDA) has released its clinical hold on Neurizon Therapeutics’ NUZ‑001, paving the way for…
